Fig. 3
Correlation between pretreatment ALC and prognosis of chemotherapy. Kaplan–Meier PFS curves of PEM + Platinum ± Bev (a), PTX + Platinum ± Bev (b), and Kaplan–Meier OS curve of first-line PEM + Platinum ± Bev (c), PTX + Platinum ± Bev (d) are shown. Patients were divided into three groups: high ALC group (ALC ≥ 2000), intermediate ALC group (2000 > ALC ≥ 1000), and low ALC group (ALC < 1000). High ALC is related to better prognosis of PEM + Platinum ± Bev. PFS = progression-free survival, ALC = absolute lymphocyte count (/mm3), PEM = Pemetrexed, PTX = Paclitaxel, Platinum = Cisplatin or Carboplatin, Bev = Bevacizumab